The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992) (Q28207228)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

title

The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

malignant pleural mesothelioma

17 December 2019

main subject

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Francesco Grossi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Nico van Zandwijk

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Giuseppe Giaccone

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

P Baas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

A Ardizzoni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

K Nackaerts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

G Numico

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

E Van Marck

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

M van de Vijver

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

F Monetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

M J A Smid-Geirnaerdt

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

C Debruyne

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

C Legrand

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

EORTC Lung Cancer Group

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

language of work or name

English

0 references

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

17 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

353-357

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

17 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Caelyx in malignant mesothelioma: a phase II EORTC study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Raltitrexed: current clinical status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900668-8

7 January 2021

10.1016/S0959-8049(02)00668-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12565988%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference